Related Experiment Videos
alpha4 integrin in islet allograft rejection
M D Stegall1, P G Dean, D Ninova
1The Transplantation Research Laboratory, Department of Surgery, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
Transplantation
|July 4, 2001
Summary
Blocking alpha4 integrin interactions with its ligands, vascular cell adhesion molecule-1 (VCAM-1) and fibronectin, significantly improves islet allograft survival. This approach may offer novel immunosuppression strategies for preventing organ transplant rejection.
Area of Science:
- Immunology
- Transplantation Biology
- Molecular Medicine
Background:
- Adhesion molecules play a crucial role in allograft rejection processes.
- Understanding these interactions is key to developing new immunosuppression strategies.
Purpose of the Study:
- To investigate the impact of blocking alpha4 integrin interactions with VCAM-1 and fibronectin on islet allograft survival.
- To evaluate the therapeutic potential of targeting alpha4 integrin pathways in transplantation.
Main Methods:
- Islet transplantation in streptozotocin-induced diabetic mice.
- Treatment with antibodies against alpha4 integrin and VCAM-1, and a CS1-peptide.
- Assessment of graft function via blood glucose levels and immunohistochemical analysis.
Main Results:
- Long-term survival of islet allografts was achieved with anti-alpha4 integrin antibody, anti-VCAM-1 antibody, and CS1-peptide treatment.
- Anti-alpha4 integrin antibody and CS1-peptide abolished cellular infiltration into the graft.
- Anti-VCAM-1 treatment showed peri-islet infiltration of activated T cells, despite graft survival.
Conclusions:
- Alpha4 integrin is essential for allograft rejection.
- Targeting alpha4 integrin or its ligands (VCAM-1, fibronectin) can prolong allograft survival.
- Blocking alpha4 integrin interactions presents a promising avenue for novel immunosuppressive therapies.